25 completed, 7 terminated, 4 not yet recruiting, 4 recruiting. 24 Phase 2, 7 Not applicable, 5 Phase 1, 3 Early Phase 1, 2 Phase 3.
Follow Neurofibromatosis 2: new trials by email Literature Review of Neurofibromatosis 2 trials Research Report on Neurofibromatosis 2
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Selumetinib for NF2-Related Schwannomatosis Selumetinib - Neurofibromatosis Type 2, NF2 | Phase 2 | Not yet recruiting | Beijing Tiantan Hospital | 20 | 2026-12-01 | 2026-10-28 |
| Luvometinib in Combination With Serplulimab for NF2-Related Tumors Luvometinib, Serplulimab - NF2-related Schwannomatosis, NF2 | Phase 1 / Phase 2 | Not yet recruiting | Beijing Tiantan Hospital | 30 | 2026-07-31 | 2026-07-16 |
| Platform Research for Innovative Medicines in NF2-SWN (PRIME-NF2) Selumetinib 25mg/m2, Luvometinib, Serplulimab - Neurofibromatosis Type 2, Vestibular Schwannoma | Phase 2 | Not yet recruiting | Beijing Tiantan Hospital | 200 | 2026-07-18 | 2026-07-20 |
| Study to Determine Optimal Dose, Evaluate the Efficacy and Safety of PRG-N-01 in Patients With Neurofibromatosis Type II Trineumin - Neurofibromatosis Type II, NF2 | Phase 1 / Phase 2 | Not yet recruiting | PRG Science & Technology Co., Ltd. | 25 | 2026-07-01 | 2026-01-23 |
| Assessment of Patient Experience With Auto-Captioning Glasses in NF2-Related-Schwannomatosis Auto-captioning Glasses - NF2-related Schwannomatosis | Not applicable | Completed | Massachusetts General Hospital | 18 | 2026-02-19 | 2026-08-25 |
| 89Zr-Bevacizumab PET/CT Imaging in NF2 Patients Bevacizumab Zirconium Zr-89 - Neurofibromatosis 2 | Unknown | Leiden University Medical Center | 15 | 2022-10-20 | 2024-03-20 | |
| Doxycycline in Cutaneous Schwannoma (NF2) Doxycycline Injection [Doxy] - Neurofibromatosis Type 2 | Phase 1 / Phase 2 | Active not recruiting | Massachusetts Eye and Ear Infirmary | 19 | 2022-09-19 | 2026-10-16 |
| Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated Meningiomas REC-2282, Placebo - Neurofibromatosis Type 2 | Phase 2 / Phase 3 | Terminated | Recursion Pharmaceuticals Inc. | 25 | 2022-06-20 | 2026-08-17 |
| MElanoma Research Lymph Node Prediction Implementation National_001 Melanoma | Active not recruiting | SkylineDx | 1820 | 2021-08-25 | 2026-04-23 | |
| Vestibular Precision: Physiology & Pathophysiology VOR precision training - Vestibular Schwannoma, Inner Ear Disease | Not applicable | Unknown | Massachusetts Eye and Ear Infirmary | 90 | 2020-07-01 | 2023-03-16 |
| Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2) Brigatinib, Neratinib, Retifanlimab - Neurofibromatosis Type 2, Vestibular Schwannoma | Phase 2 | Recruiting | Scott R. Plotkin, MD, PhD | 109 | 2020-06-20 | 2026-10-28 |
| Phase 2 Clinical Trial of Crizotinib for Children and Adults With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas Crizotinib - Neurofibromatosis 2, Progressive Vestibular Schwannoma (VS) | Phase 2 | Completed | University of Alabama at Birmingham | 12 | 2020-02-18 | 2026-03-13 |
| Cutaneous and Mucosal Manifestations of Neurofribromatosis Type 2 in Children Under 15 no intervention - Neurofibromatosis 2, Dermatology/Skin - Other | Recruiting | Centre Hospitalier Universitaire de Nice | 1000 | 2019-01-01 | 2026-06-29 | |
| Study of Safety and Efficacy of Brolucizumab 6 mg Dosed Every 4 Weeks Compared to Aflibercept 2 mg Dosed Every 4 Weeks in Patients With Retinal Fluid Despite Frequent Anti-VEGF Injections Brolucizumab, Aflibercept - Age-Related Macular Degeneration | Phase 3 | Terminated | Novartis Pharmaceuticals | 535 | 2018-10-30 | 2023-01-30 |
| A Single Center Pilot Study to Assess the Intra-observer Reliability of Measuring Muscle Strength Using a Hand Held Dynamometer in Children and Adults With Neurofibromatosis Type 1 (NF1) and Type 2 (NF2) hand-held dynamometer - Neurofibromatosis 1 and 2 (NF1 and NF2) | Not applicable | Completed | NYU Langone Health | 33 | 2018-09-24 | 2021-03-18 |
| Study of Aspirin in Patients With Vestibular Schwannoma Aspirin, Placebo - Vestibular Schwannoma, Acoustic Neuroma | Phase 2 | Active not recruiting | Massachusetts Eye and Ear Infirmary | 97 | 2018-03-01 | 2026-10-16 |
| Resiliency Training for Adults With Neurofibromatosis Via Live Videoconferencing Stress and Symptom Management Program 1, Stress and Symptom Management Program 2 - Neurofibromatoses, Neurofibromatosis 1 | Not applicable | Completed | Massachusetts General Hospital | 228 | 2017-10-01 | 2025-12-24 |
| WES of NF2-associated in Comparison to Sporadic Vestibular Schwannomas - Correlation With Clinical Data Whole exome sequencing - Neurofibromatosis Type 2, Vestibular Schwannoma | Completed | University Hospital Tuebingen | 70 | 2017-07-31 | 2018-07-23 | |
| Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors Selumetinib - Neurofibromatosis 2, Vestibular Schwannoma | Phase 2 | Terminated | Children's Hospital Medical Center, Cincinnati | 10 | 2017-05-08 | 2025-04-22 |
| Familial Investigations of Childhood Cancer Predisposition Acute Leukemia, Adenomatous Polyposis | Recruiting | St. Jude Children's Research Hospital | 1500 | 2017-04-06 | 2026-06-17 |
Showing 20 of 47. Sign in to see all of them.
Neuroma, Acoustic (23) · Meningioma (12) · Neurofibromatoses (7) · Neurofibromatosis 1 (7) · Ependymoma (6) · Schwannomatosis (3) · Brain Neoplasms (2) · Hearing Loss (2) · Melanoma (2) · Neoplasms (2) · Neurilemmoma (2) · Vestibular Diseases (2) · Adenomatous Polyposis Coli (1) · Adrenocortical Carcinoma (1)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (47) · Cranial Nerve Diseases (47) · Cranial Nerve Neoplasms (47) · Ear Diseases (47) · Heredodegenerative Disorders, Nervous System (47) · Neoplasms by Histologic Type (47) · Neoplasms, Germ Cell and Embryonal (47) · Neoplasms, Nerve Tissue (47) · Neoplastic Syndromes, Hereditary (47) · Nerve Sheath Neoplasms (47) · Neurocutaneous Syndromes (47) · Neurodegenerative Diseases (47) · Neuroectodermal Tumors (47) · Neuroendocrine Tumors (47) · Neurofibroma (47)
Bevacizumab (6) · Everolimus (4) · AZD 6244 (3) · HDAC-42 (2) · Lapatinib (2) · Sirolimus (2) · 89Zr-bevacizumab (1) · Aspirin (1) · Axitinib (1) · Cetuximab (1) · Crizotinib (1) · Disulfides (1) · Doxycycline (1) · Endostatins (1) · Exome (1)
Massachusetts Eye and Ear Infirmary (5) · Massachusetts General Hospital (5) · NYU Langone Health (5) · Beijing Tiantan Hospital (4) · FDA Office of Orphan Products Development (2) · University of Alabama at Birmingham (2) · Assistance Publique - Hôpitaux de Paris (1) · Centre Hospitalier Universitaire de Nice (1) · Children's Hospital Medical Center, Cincinnati (1) · Guy's and St Thomas' NHS Foundation Trust (1) · House Ear Institute (1) · Jonsson Comprehensive Cancer Center (1) · Leiden University Medical Center (1) · Li Peng (1) · M.D. Anderson Cancer Center (1)
United States (34) · China (5) · United Kingdom (3) · France (2) · Germany (1) · Netherlands (1) · Puerto Rico (1)
Ana-Maria Vranceanu, PhD (3) · Matthias A Karajannis, MD, MS (3) · D. Bradley Welling, MD, PhD (2) · Fu Zhao (2) · Pinan Liu (2) · Scott Plotkin, MD (2) · Theodore Nicolaides, MD (2) · Brad Welling, MD, PhD (1) · Girish Dhall, MD (1) · Hans AJ Gelderblom, MD, PhD (1) · Jaishri Blakeley (1) · Jaishri O Blakeley, MD (1) · Jay Barth, MD (1) · John D Heiss, M.D. (1) · Kaleb H Yohay, MD (1)
PMID 26933802, PMID 26943915, PMID 26976425, PMID 30355560, PMID 32421171, PMID 34409538, PMID 34570301, PMID 34667843, PMID 35064449, PMID 35925531, PMID 36651958, PMID 37311055, PMID 37378983, PMID 37440099, PMID 38318960, PMID 38372904, PMID 38904277, PMID 39917761, PMID 40773151, PMID 41389341, PMID 41951260
P30CA006973 (1)